Barrowcliffe Susan E. 4
4 · Aimmune Therapeutics, Inc. · Filed Nov 21, 2018
Insider Transaction Report
Form 4
Barrowcliffe Susan E.
General Manager, Europe
Transactions
- Exercise/Conversion
Common Stock, $0.0001 par value
2018-11-19$3.02/sh+40,000$120,880→ 49,375 total - Sale
Common Stock, $0.0001 par value
2018-11-19$30.04/sh−40,000$1,201,600→ 9,375 total - Exercise/Conversion
Stock Option (right to buy)
2018-11-19−40,000→ 53,400 totalExercise: $3.02Exp: 2025-05-13→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]Includes restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F2]The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.